Table 5. Meta-analysis of primary and secondary outcomes.
| Outcome | No. of patients | No. of studies | RR/WMD (95% CI) | P value | Heterogeneity, I2 |
|---|---|---|---|---|---|
| Mortality | 2,221 | 14 | 0.84 (0.65–1.09) | 0.20 | 0 |
| Temporary neurological dysfunction | 954 | 8 | 0.77 (0.56–1.07) | 0.13 | 0 |
| Permanent neurological dysfunction | 1,938 | 11 | 0.82 (0.52–1.31) | 0.42 | 15 |
| New-onset stroke | 1,458 | 8 | 0.88 (0.48–1.62) | 0.68 | 0 |
| Renal dialysis | 1,955 | 10 | 0.72 (0.56–0.94) | 0.02 | 0 |
| Ventilation >72 hours | 861 | 7 | 0.77 (0.55–1.08) | 0.13 | 0 |
| Cardiopulmonary bypass time | 1,966 | 11 | −47.86 (−44.37 to 51.35) | <0.00001 | 97 |
| Cross clamp time | 1,225 | 7 | −18.68 (−5.94 to 31.43) | <0.0001 | 95 |
| Circulatory arrest time | 1,195 | 7 | −10.73 (−3.39 to 18.07) | <0.00001 | 97 |
| Rate of aortic re-operation (proximal and distal) | 1,651 | 12 | 1.45 (0.93–2.28) | 0.10 | 23 |
RR, risk ratio; CI, confidence interval; WMD, weighted mean difference.